Breast cancer relapses considering molecular biological characteristics.
| Autor: | Smolanka II; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Movchan OV; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Bagmut IY; Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine., Sheremet MI; Department of Surgery No.1, Bukovinian State Medical University, Chernivtsi, Ukraine., Kolisnyk IL; Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine., Dosenko IV; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Lyashcnko AO; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Ivankova OM; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Loboda AD; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Shidlovskyi OV; Department of Surgery, Ivan Horhachevsky Ternopil National Medical University, Ternopil, Ukraine. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of medicine and life [J Med Life] 2023 Jan; Vol. 16 (1), pp. 70-75. |
| DOI: | 10.25122/jml-2022-0189 |
| Abstrakt: | We aimed to analyze the frequency of breast cancer relapses and their relationship with molecular and biological tumor characteristics. We studied 6,136 breast cancer patients, including 146 with relapses (Group 1) and 455 without relapses (Group 2). We divided the patients based on age, menstrual function, disease stage, histology form and grade, and molecular-biological subtype. The 5-year relapse-free rate for Group 1 was longer for Lum A and TN subtypes (60% and 40%, respectively) but shorter for Lum B and HER-2/neu-amplified subtypes (38% and 31%, respectively). Disease stage, tumor histology, and grade did not significantly affect relapse frequency in these patients. Relapses were more common in premenopausal patients and the Lum B subtype. Competing Interests: The authors declare no conflict of interest. (©2022 JOURNAL of MEDICINE and LIFE.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|